Cytori Therapeutics (CYTX) Receiving Somewhat Favorable Media Coverage, Analysis Finds
Media stories about Cytori Therapeutics (NASDAQ:CYTX) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cytori Therapeutics earned a news impact score of 0.23 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 46.0636647584952 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern Sentiment’s analysis:
- Cytori Therapeutics (CYTX) Lowered to “Sell” at Zacks Investment Research (americanbankingnews.com)
- Cytori Therapeutics (CYTX) Given a $4.00 Price Target at Maxim Group (americanbankingnews.com)
- Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $80,292.70 in Stock (americanbankingnews.com)
- Cytori Therapeutics Announces Inducement Grants for New Employees (finance.yahoo.com)
- Comparing Antares Pharma (ATRS) and Cytori Therapeutics (CYTX) (americanbankingnews.com)
CYTX has been the topic of several research reports. Maxim Group set a $5.00 price target on Cytori Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 19th. B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a research note on Tuesday, November 7th. Zacks Investment Research lowered Cytori Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Finally, ValuEngine upgraded Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd.
In other news, major shareholder Ag Postfinance sold 236,155 shares of the company’s stock in a transaction that occurred on Friday, February 9th. The stock was sold at an average price of $0.34, for a total value of $80,292.70. Following the sale, the insider now directly owns 5,311,451 shares in the company, valued at approximately $1,805,893.34. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Bank Sa Swissquote sold 100,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $0.38, for a total value of $38,000.00. Following the completion of the sale, the insider now owns 5,496,655 shares in the company, valued at $2,088,728.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 408,785 shares of company stock worth $142,987. Corporate insiders own 1.90% of the company’s stock.
TRADEMARK VIOLATION WARNING: This article was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://theolympiareport.com/2018/02/14/cytori-therapeutics-cytx-receiving-somewhat-favorable-media-coverage-analysis-finds.html.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.